3-(2-氨基乙基)-噻唑烷-2,4-二酮盐酸盐 | 19382-49-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 3-(2-氨基乙基)-噻唑烷-2,4-二酮盐酸盐
• 英文名称: 3-(2-aminoethyl)-2,4-thiazolidinedione hydrochloride
• 英文别名: 3-(2-aminoethyl)thiazolidine-2,4-dione hydrochloride；3-(2-Amino-aethyl)-thiazolidin-2,4-dion; Hydrochlorid；3-(2-aminoethyl)-1,3-thiazolidine-2,4-dione hydrochloride；3-(2-Amino-ethyl)-thiazolidine-2,4-dione;hydrochloride；2-(2,4-dioxo-1,3-thiazolidin-3-yl)ethylazanium;chloride
• CAS: 19382-49-1
• 化学式: C₅H₈N₂O₂S*ClH
• mdl: MFCD00801011
• 分子量: 196.658
• InChiKey: XXSVYLLONFKJSO-UHFFFAOYSA-N

物化性质

• 熔点：
  227-228 °C(Solv: ethanol (64-17-5))
• 密度：
  1.411

计算性质

• 辛醇/水分配系数(LogP)：
  -0.85
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  88.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 储存条件：
  存储条件：室温、密封、干燥

反应信息

• 作为反应物：
  描述：

  3-(2-氨基乙基)-噻唑烷-2,4-二酮盐酸盐 在 potassium carbonate 、 caesium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 10.0h， 生成 2-[2-[2-(2,4-Dioxo-1,3-thiazolidin-3-yl)ethyl-methylamino]-2-oxoethyl]sulfanylacetic acid
  参考文献：
  名称：

  WO2019183577A5

  摘要：

  公开号：

  WO2019183577A5
• 作为产物：
  描述：

  ethyl [(4,5-dihydro-2-imidazolyl)thio]acetate hydrochloride 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以60%的产率得到3-(2-氨基乙基)-噻唑烷-2,4-二酮盐酸盐
  参考文献：
  名称：

  New data on the alkylation of cyclic thioureas with α-halo-carboxylic acids and their esters. 1. Alkylation of ethylene thiourea

  摘要：

  DOI：

  10.1007/s10593-006-0075-5

文献信息

• Aryl compounds with aminoalkyl substituents and their use
  申请人：Härter Michael

  公开号：US20110312930A1

  公开（公告）日：2011-12-22

  The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有氨基烷基取代基的新型芳基化合物，涉及其制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应低氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• Modulators of G-protein coupled receptors
  申请人：Carmot Therapeutics, Inc.

  公开号：US11535660B1

  公开（公告）日：2022-12-27

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon?like peptide?1 receptor (“GLP?1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP?1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancement of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP?1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple)-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

  本公开的化学实体（如化合物或该化合物的药学上可接受的盐和/或水合物和/或原药）可调节（如激动或部分激动或拮抗）胰高血糖素样肽1受体（"GLP?1R"）和/或胃抑制多肽受体（"GIPR"）。这些化学实体是有用的，例如，用于治疗患有疾病、失调或病症的受试者（例如人类），在这种情况下，调节（例如，激动、部分激动或拮抗）GLP?1R 和/或 GIPR 的活性有利于治疗或预防潜在的病理和/或症状和/或疾病、失调或病症的进展。在一些实施方案中，调节的结果是增强（如增加）现有水平（如正常或低于正常水平）的GLP?1R和/或GIPR活性（如信号传导）。在某些实施方案中，本文所述的化学实体可进一步调节（如减弱、解除耦合）--相对于原生配体的信号转导。本公开还包括组合物以及使用和制造所述化学实体的其他方法。
• The Rearrangement of 2-Carboxymethylmercaptoimidazolidine
  作者：JAMES A. VanALLAN

  DOI：10.1021/jo01108a011

  日期：1956.2
• MODULATORS OF G-PROTEIN COUPLED RECEPTORS
  申请人：Carmot Therapeutics, Inc.

  公开号：EP3768294A1

  公开（公告）日：2021-01-27
• [EN] MODULATORS OF G-PROTEIN COUPLED RECEPTORS<br/>[FR] MODULATEURS DE RÉCEPTEURS COUPLÉS À LA PROTÉINE
  申请人：CARMOT THERAPEUTICS INC

  公开号：WO2019183577A1

  公开（公告）日：2019-09-26

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon?like peptide?1 receptor ("GLP?1R") and/or the gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP?1R and/or GIPR activities is benficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancment of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP?1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) -arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.